ShareSoc webinar – Meet the analyst: Immuno-oncology

Immuno-oncology is entering a new phase of innovation as first-generation checkpoint inhibitors approach clinical and commercial maturity. In our recent webinar (Redesigning immunity: The next frontier in immuno-oncology), we outline how next-generation platforms, including novel checkpoints, cancer vaccines (act as immune-priming partners) and increasingly scalable CAR-T and cell therapy approaches are designed to overcome resistance, expand responder populations and move treatment into earlier disease settings. We also discuss the approaching big pharma patent cliff (over $200bn in branded sales at risk by 2030) and the strategic and partnering implications of this shift. We outline how companies with differentiated biology and scalable technologies are best positioned to capture the next wave of value creation in oncology. The session provides a clear framework for identifying the companies best positioned to benefit from the next wave of immuno-oncology.